Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH/IGF-1 Axis in Ataxia Telangiectasia
NCT01052623Phase 4Unknown
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jan 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin (HL-032 oral tablet biobetter) in Growth failure (FTT), sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Growth Hormone increase after Arginine Provocation Test. Status: unknown.
02
Drugs
somatropin (HL-032 oral tablet biobetter)
03
Conditions
Growth failure (FTT)
Beyond the preview
Go deeper on NCT01052623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052623.